Literature DB >> 11171773

Hospital-acquired pneumonia: risk factors, microbiology, and treatment.

J P Lynch1.   

Abstract

Pneumonia complicates hospitalization in 0.5 to 2.0% of patients and is associated with considerable morbidity and mortality. Risk factors for hospital-acquired pneumonia (HAP) include mechanical ventilation for > 48 h, residence in an ICU, duration of ICU or hospital stay, severity of underlying illness, and presence of comorbidities. Pseudomonas aeruginosa, Staphylococcus aureus, and Enterobacter are the most common causes of HAP. Nearly half of HAP cases are polymicrobial. In patients receiving mechanical ventilation, P aeruginosa, Acinetobacter, methicillin-resistant S aureus, and other antibiotic-resistant bacteria assume increasing importance. Optimal therapy for HAP should take into account severity of illness, demographics, specific pathogens involved, and risk factors for antimicrobial resistance. When P aeruginosa is implicated, monotherapy, even with broad-spectrum antibiotics, is associated with rapid evolution of resistance and a high rate of clinical failures. For pseudomonal HAP, we advise combination therapy with an antipseudomonal beta-lactam plus an aminoglycoside or a fluoroquinolone (eg, ciprofloxacin).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171773     DOI: 10.1378/chest.119.2_suppl.373s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  40 in total

Review 1.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

2.  Pseudomonas aeruginosa infection liberates transmissible, cytotoxic prion amyloids.

Authors:  Ron Balczon; K Adam Morrow; Chun Zhou; Bradley Edmonds; Mikhail Alexeyev; Jean-Francois Pittet; Brant M Wagener; Stephen A Moser; Silas Leavesley; Xiangming Zha; Dara W Frank; Troy Stevens
Journal:  FASEB J       Date:  2017-03-17       Impact factor: 5.191

3.  Clonality of Bacterial Pathogens Causing Hospital-Acquired Pneumonia.

Authors:  V Pudová; M Htoutou Sedláková; M Kolář
Journal:  Curr Microbiol       Date:  2016-05-12       Impact factor: 2.188

4.  Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; María D Maciá; Olivia Gutiérrez; Carmen Vidal; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.

Authors:  Jared L Crandon; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

6.  Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study.

Authors:  Marta Di Pasquale; Mariano Esperatti; Ernesto Crisafulli; Miquel Ferrer; Gianluigi Li Bassi; Mariano Rinaudo; Angels Escorsell; Javier Fernandez; Antoni Mas; Francesco Blasi; Antoni Torres
Journal:  Intensive Care Med       Date:  2013-08-02       Impact factor: 17.440

7.  Aerobic Gram-negative Bacillary Pneumonia.

Authors:  Stephen Parodi; Matthew Bidwell Goetz
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

Review 8.  Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature.

Authors:  Andrew F Shorr
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain.

Authors:  Thomas A Russo; Bruce A Davidson; Diana M Topolnycky; Ruth Olson; Stacy A Morrill; Paul R Knight; Philip M Murphy
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Phenol-Soluble Modulin Peptides Contribute to Influenza A Virus-Associated Staphylococcus aureus Pneumonia.

Authors:  Dominik Alexander Bloes; Emanuel Haasbach; Carmen Hartmayer; Tobias Hertlein; Karin Klingel; Dorothee Kretschmer; Oliver Planz; Andreas Peschel
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.